MaxCyte Inc (LON: MXCT) CEO Doug Doerfler sat down with Proactive at the BIO Investor Forum in San Francisco.
Doerfler says the company is making 'exciting progress' with its early-stage cancer drug developed using its CARMA technology.
The objective of a study of this kind is to assess whether the drug is safe and well-tolerated.